
Exhale 1000mg Lab Test

At Karavie, our goal is to produce the purest end product possible. In order to do so, we test your CBD at each step of our production process.

LOT # 0018723KVASTD510





261 Mountain View Dr Colchester, VT 05446 License #: TLAB0030 802-767-7256 info@onwardanalytics.biz

Client Name: Kria Commons License Number: MANU-0005

Sample ID: VT1753

Sample Name: Karavie Assorted Gummy, 25mg CBD (Pineapple, Blackberry, Black Raspberry) Sample Lot: 0018723KVASTD510 Sample Matrix: Gummy Date Received: 5/22/2023 Date Reported: 5/27/2023 Date Tested: 5/24/2023

Certificate of Analysis



Total Cannabinoids							
	%	mg/g	mg/unit				
Total THC:	0.018	0.176					
Total CBD:	0.975	9.750	29.549				
Total Cannabinoids:	0.993	9.926	30.083				
Unit Weight (g): 3.0307							

Total theoretical CBD % = (CBD%) + (CBDA% * 0.877) Total theoretical THC % = (delta-9-THC%) + (THCA% * 0.877)

Potency

Standard potency analysis utilizing High Performance Liquid Chromatography (HPLC; SOP-024-0A) | Test ID: #3330

Analyte	%	mg/g	mg/unit	LOD (mg/g)	LOQ (mg/g)
CBDV	< LOQ	< LOQ	<loq< td=""><td>0.0008</td><td>0.0040</td></loq<>	0.0008	0.0040
CBDVA	ND	ND	ND	0.0001	0.0040
THCV	ND	ND	ND	0.0016	0.0049
CBDA	ND	ND	ND	0.0002	0.0040
CBD	0.975	9.75	29.55	0.0008	0.0040
CBG	ND	ND	ND	0.0009	0.0040
CBGA	ND	ND	ND	0.0001	0.0040
THCVA	ND	ND	ND	0.0002	0.0040
CBN	ND	ND	ND	0.0004	0.0040
CBCVA	ND	ND	ND	0.0004	0.0040
D9 THC	0.0176	0.176	0.53	0.0016	0.0049
D8 THC	ND	ND	ND	0.0012	0.0040
CBNA	ND	ND	ND	0.0002	0.0040
D10 THC	ND	ND	ND	0.0004	0.0040
CBC	< LOQ	< LOQ	<loq< td=""><td>0.0003</td><td>0.0040</td></loq<>	0.0003	0.0040
THCA	ND	ND	ND	0.0002	0.0040
CBCA	ND	ND	ND	0.0002	0.0040

Callie Chapmar

Lab Directo 5/27/2023

In performing the services, Onward Analytics, ("OA") shall exercise a degree of skill and care ordinarily exercised by a reasonably prudent laboratory professional under similar circumstances. Except as set forth in the preceding sentence, client acknowledges and agrees that: (a) the services may require OA to make judgements based upon limited data rather than upon scientific certainties; (b) OA's approach, recommendations, and associated cost estimates, if any, are based on industry practices and averages; (c) OA renders its opinions with respect to observations made and data available at the time of testing; (d) ultimate outcomes could be inconsistent with OA's conclusions, results and projections; and (e) there may be additional reports relating to the site (whether prepared by OA or other parties), and reliance upon any OA report without reference to any such other reports is done at client's sole risk.

